Login
← Go Back
Biocon
BIOCON · Pharma > Pharmaceuticals & Drugs · Chairman: Kiran Mazumdar-Shaw · MD: Siddharth Mittal · Listing date: April 8, 2004 · Employees: 13500 · Bangalore · http://www.biocon.com
Stock Price vs Company Growth
1d
5.2%
1w
17.3%
1m
19.6%
3m
18.6%
6m
37.9%
1y
32.7%
5y
-0.0%
10y
15.1%
all
15.0%
🤔 How to analyze this graph?
Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price
₹ 307 5.2%
244
313
Company Overview
Sales
14,612 Cr
Growth: 36.8%
Profit after Tax
1,179 Cr
Growth: 136.6%
Large Cap
36,858 Cr
P/E: 30.6x
Industry P/E: 35.5x
Fundamentals
Sales (Cr) ₹ 14,612
Growth 36.8%
EBITDA 23.1%
P/S 2.5x
Dividend 0.6%
P/E 30.6x
Book Value ₹ 156
PEG Ratio 0.8x
ROE 6.5%
P/B 2.0x
Shareholding Pattern
Institutions
Life Insurance Corporation Of India (Lic)
4.11 %
Ahan- I Ltd
1.66 %
Qualified Institutional Buyer
0.61 %
Promoters
Kiran Mazumdar Shaw
39.62 %
Glentec International
19.76 %
John Mccallum Marshall Shaw
0.7 %
Ravi Rasendra Mazumdar
0.4 %
Yamini R Mazumdar
0.11 %
Others
Arun Suresh Chandavarkar
1.1 %
Beneficial Holdings Under Mgt-4
0.46 %
Iepf
0.01 %
Increase    Decrease    No change
Company Profile Detailed
The company is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as generic formulations in the US and Europe. It also has a pipeline of promising novel assets in immunotherapy under development.
Belongs to (26 Indices) view more
Investors (374)
mahesh.g...
swiss.fi...
syed.sal...
Followers (41)
kiran198...
deepak
nitin2